Voice-activated Intelligent Personal Assistant (VIPA) Intervention for People With Parkinson's Disease

NCT06036771 | Completed

• 1 other identifier: HSEARS20221107005
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

This pilot randomized control trial (RCT) aims to develop a Voice-activated Intelligent Personal Assistance (VIPA) user protocol and study its feasibility and preliminary efficacy among 48 People with Parkinson's disease (PWP). The research questions are: Phase 1:

1. 1.What components should be included in the VIPA user protocol community-dwelling PWP?
2. 2.Is it feasible to implement the VIPA intervention in the PD population?
3. 3.What is the preliminary efficacy of VIPA intervention on SOC and psychosocial well-being?
4. 4.Can such effect sustain for 4 weeks?
5. 5.What is the users' experience on the VIPA intervention?
6. 6.User protocol
7. 7.Designate VIPA
8. 8.30-minute VIPA training on day 1
9. 9.technical support hotline. CG participants will receive usual care, no intervention will be provided to CG participants, and they will continue their daily life during the intervention period.

Conditions

Parkinson's Disease and Parkinsonism

Keywords

sense of coherence; psychosocial well-being; Voice-activated Intelligence Personal assistant

Outcome Measures

Primary Outcomes (1)

• 13-item Sense of Coherence Scale

  The 13-item Sense of Coherence Scale is a 13 item, 7-point Likert scale that measures PWP's sense of coherence. Its score ranges from 13-91, with a higher score representing a higher sense of coherence.

  [Time Frame: Baseline; 8 weeks; 12 weeks]

Secondary Outcomes (8)

• UCLA three-item loneliness scale

  [Time Frame: Baseline; 8 weeks; 12 weeks]

• Parkinson's Disease Questionnaire (PDQ-8)

  [Time Frame: Baseline; 8 weeks; 12 weeks]

• EuroQol- 5 dimension- 5 level

  [Time Frame: Baseline]

• Mental Health Continuum Short Form

  [Time Frame: Baseline; 8 weeks; 12 weeks]

• Brief Resilient Coping Scale

  [Time Frame: Baseline; 8 weeks; 12 weeks]

Study Arms (2)

Voice-activated Intelligent Personal Assistant (VIPA) intervention

EXPERIMENTAL

IG participants will receive 1. The developed VIPA user protocol 2. 30-minute training session on day 1 3. Technical support hotline Dosage of the intervention: PWP are encouraged to perform 10 voice commands/ day during the 8-week intervention period, self-reported usage will be documented by participants in a progress note.

Device: Voice-activated Intelligent Personal Assistant (VIPA)

Usual care, no intervention provided

NO INTERVENTION

CG participants will be placed under usual care, no intervention will be provided and PWP will continue their daily life during the intervention period

Interventions

Voice-activated Intelligent Personal Assistant (VIPA) DEVICE

Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese

Voice-activated Intelligent Personal Assistant (VIPA) intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Cantonese-speaking Hong Kong permanent resident
• Diagnosed with Parkinson's disease
• Level 1-4 in the H\&Y scale (Hoehn \& Yahr, 1967)
• Not currently using or owning VIPA
• Has stable Wi-Fi connection at home.

You may not qualify if:

• PWP or their caregivers that fails to provide valid consent
• Individuals with hearing loss in both ears
• Severe voice impairment
• Dementia patients (MoCA score \<21)
• PWP will leave Hong Kong during the intervention period.

Sponsors & Collaborators

• The Hong Kong Polytechnic University: lead

Study Sites (1)

The Hong Kong Polytechnic University

Kowloon, Hong Kong, 0000, Hong Kong

Location

Related Publications (11)

• Arnold A, Kolody S, Comeau A, Miguel Cruz A. What does the literature say about the use of personal voice assistants in older adults? A scoping review. Disabil Rehabil Assist Technol. 2024 Jan;19(1):100-111. doi: 10.1080/17483107.2022.2065369. Epub 2022 Apr 22.

  PMID: 35459429 BACKGROUND

• Antonovsky, A. (1987). Unravelling the mystery of health: How people manage stress

  BACKGROUND

• Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychology and Health, 12(6), 805-814.

  BACKGROUND

• Szende A, Janssen B, Cabases J, editors. Self-Reported Population Health: An International Perspective based on EQ-5D [Internet]. Dordrecht (NL): Springer; 2014. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK500356/

  PMID: 29787044 BACKGROUND

• Lamers SM, Westerhof GJ, Bohlmeijer ET, ten Klooster PM, Keyes CL. Evaluating the psychometric properties of the Mental Health Continuum-Short Form (MHC-SF). J Clin Psychol. 2011 Jan;67(1):99-110. doi: 10.1002/jclp.20741.

  PMID: 20973032 BACKGROUND

• Brooke, J. (1996). SUS-A quick and dirty usability scale. Usability evaluation in industry, 189(194), 4-7.

  BACKGROUND

• Sinclair VG, Wallston KA. The development and psychometric evaluation of the Brief Resilient Coping Scale. Assessment. 2004 Mar;11(1):94-101. doi: 10.1177/1073191103258144.

  PMID: 14994958 BACKGROUND

• Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.

  PMID: 15817019 BACKGROUND

• Subramanian I, Hinkle JT, Chaudhuri KR, Mari Z, Fernandez H, Pontone GM. Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease. Parkinsonism Relat Disord. 2021 Dec;93:97-102. doi: 10.1016/j.parkreldis.2021.11.015. Epub 2021 Nov 27.

  PMID: 34887173 BACKGROUND

• Cools CI, de Vries NM, Bloem BR. Happiness: A Novel Outcome in Parkinson Studies? J Parkinsons Dis. 2020;10(3):1261-1266. doi: 10.3233/JPD-201999.

  PMID: 32568107 BACKGROUND

• NIEHS(2021). Neurodegenerative Diseases. Retrieved from United States Department of Health and Human Services, The National Institute of Environmental Health Sciences (NIEHS) Web site: https://www.niehs.nih.gov/research/supported/health/neurodegenerative/index.cfm

  BACKGROUND

MeSH Terms

Conditions

Parkinson Disease; Parkinsonian Disorders

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: outcome assessors will be blinded to the group allocation.
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: 48 PWP will be randomized into the intervention group (IG) and controlled group (CG). Block randomization is performed by an independent research team member who will not be in contact with participants via a free third-party website. Allocations will only be revealed upon the commencement of the intervention period and cannot be altered.

Study Record Dates

• First Submitted: August 21, 2023
• First Posted: September 14, 2023
• Study Start: August 6, 2023
• Primary Completion: March 31, 2025
• Study Completion: May 31, 2025
• Last Updated: January 21, 2026

Record last verified: 2023-09

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)